Close Menu

Precision Oncology Regulatory News

The latest headlines on diagnostics regulation: FDA, CMS, and international regulatory agencies.

The FDA approved FoundationOne CDx as a companion diagnostic for olaparib for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer.

Regulators in the country granted additional approval of the test as a companion diagnostic for Rozlytrek, marketed in Japan by Roche's Chugai Pharmaceutical.

The FDA and its pediatric oncology drugs advisory committee heard at a recent meeting how the drug is allowing some to live longer than expected, without toxicities.

MSK-ACCESS sequences 129 cancer-associated genes selected from the MSK-IMPACT assay and is designed to detect gene alterations in cfDNA specimen.

The LeukoStrat CDx FLT3 Mutation Assay can now be used in Japan as the CDx for quizartinib for the treatment of FLT3-ITD positive relapsed or refractory AML.